Your email has been successfully added to our mailing list.

×
0.000383362085489669 0.00115104466168303 0.00134176729921411 -0.000622963388920814 -0.0014376078205866 -0.0014376078205866 -0.0014376078205866 -0.0014376078205866
Stock impact report

Morgan Stanley starts CervoMed at overweight, cites upcoming data [Seeking Alpha]

Morgan Stanley (MS) 
Last morgan stanley earnings: 4/16 07:15 am Check Earnings Report
US:NYSE Investor Relations: morganstanley.com/about-us-ir
Company Research Source: Seeking Alpha
The investment bank said it sees the risk/reward for the stock as skewed to the upside ahead of a Phase 2b readout for dementia with Lewy bodies expected in December, with the potential for shares to trade up more than 100-150% with positive data or down 65-75% with disappointing data. Morgan Stanley also sees additional potential value for the drug in the treatment of early Alzheimer's and indications such as ischemic stroke. The bank set its price target for the stock at $35. Recommended For You More Trending News Recommended For You More Trending News About CRVO Stock Related Stocks Trending Analysis Trending News Show less Read more
Impact Snapshot
Event Time:
MS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for MS alerts
Opt-in for
MS alerts

from News Quantified
Opt-in for
MS alerts

from News Quantified